Novan (NOVN) – Business Wire
-
Ligand Reports Second Quarter 2023 Financial Results
-
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
-
Ligand Reports First Quarter 2023 Financial Results
-
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
-
AavantiBio Further Enhances Leadership Team with Appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer
-
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
-
Pritzker Private Capital Appoints Paula Brown Stafford to Pritzker Advisory Board
-
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
-
Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
-
Shannon Thyme Klinger Joins Moderna as Chief Legal Officer and Corporate Secretary
-
Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors
-
Carrols Restaurant Group, Inc. Names Markus Hartmann as General Counsel
-
François Nader, M.D., Joins Moderna’s Board of Directors
Back to NOVN Stock Lookup
